

FRANCE TRANSPARENCY REPORT - Angelini Pharma

Date of publication 30/06/2021

	Full name (Art. 1.01)	HCPs: City of Principal Practice HCOs: city where registered (Art. 3)	Country of Principal Practice (Schedule 1)	Principal Practice Address (Art. 3)	Unique country identifier OPTIONAL (Art. 3)	Donations and Grants to HCOs (Art. 3.01.1.a)	Contribution to costs of Events (Art. 3.01.1.b & 3.01.2.a)			Fee for service and consultancy (Art. 3.01.1.c & 3.01.2.c)			TOTAL OPTIONAL	
							Sponsorship agreements with HCOs / third parties appointed by HCOs to manage an Event	Registration Fees	Travel & Accommodation	Fees	Related expenses agreed in the fee for service or consultancy contract, including travel & accommodation relevant to the contract			
INDIVIDUAL NAMED DISCLOSURE - one line per HCP (i.e. all transfers of value during a year for an individual HCP will be summed up: itemization should be available for the individual Recipient or public authorities' consultation only, as appropriate)														
HCPs	Attal Nadine	Paris	France	3 Avenue Victoria, 75004	-	N/A	N/A	-	-	3.500,00 €	-		3.500,00 €	
	Bensadoun Renè-Jean	Nice	France	42 Av. Georges Clemenceau	-	N/A	N/A	-	-	3.000,00 €	-		3.000,00 €	
	Bouhassira Didier	Versailles	France	55 Avenue de Paris	-	N/A	N/A	-	-	3.000,00 €	-		3.000,00 €	
	OTHER, NOT INCLUDED ABOVE - where information cannot be disclosed on an individual basis for legal reasons													
Aggregate amount attributable to transfers of value to such Recipients - Art. 3.02						N/A	N/A	-	-	-	-		-	
Number of Recipients in aggregate disclosure - Art. 3.02						N/A	N/A	-	-	-	-		-	
% of the number of Recipients included in the aggregate disclosure in the total number, by category, of Recipients disclosed - Art. 3.02						N/A	N/A	-	-	-	-		-	
INDIVIDUAL NAMED DISCLOSURE - one line per HCO (i.e. all transfers of value during a year for an individual HCO will be summed up: itemization should be available for the individual Recipient or public authorities' consultation only, as appropriate)														
HCOs	-	-	-	-	-	-	-	-	-	-	-		-	
	OTHER, NOT INCLUDED ABOVE - where information cannot be disclosed on an individual basis for legal reasons													
	Aggregate amount attributable to transfers of value to such Recipients - Art. 3.02						-	-	-	-	-	-		-
	Number of Recipients in aggregate disclosure - Art. 3.02						-	-	-	-	-	-		-
% of the number of Recipients included in the aggregate disclosure in the total number, by category, of Recipients disclosed - Art. 3.02						-	-	-	-	-	-		-	
R&D	AGGREGATE DISCLOSURE													
	Transfers of Value re Research & Development as defined - Article 3.04 and Schedule 1												-	